We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......

Basic View | Expanded View
 Showing 21-40 of 44 Articles
Axel Montagne, PhD; Arthur W. Toga, PhD; Berislav V. Zlokovic, MD, PhD

This Viewpoint discusses the benefits and risks of gadolinium-based contrast agents used in magnetic resonance imaging in relation to blood-brain barrier permeability.

Original Investigation 
Robert A. Hauser, MD; Fabrizio Stocchi, MD; Olivier Rascol, MD; Susan B. Huyck, DrPH; Rachel Capece, BS; Tony W. Ho, MD; Peter Sklar, MD; Christopher Lines, PhD; David Michelson, MD; David Hewitt, MD
Includes: Supplemental Content

Importance  Preladenant is an adenosine 2A receptor antagonist that reduced “off” time in a placebo-controlled phase 2b trial in patients with Parkinson disease (PD). We sought to confirm its efficacy in phase 3 trials.

Objective  To evaluate preladenant as an adjunct to levodopa in patients with ...

Original Investigation 
Thabele M. Leslie-Mazwi, MD; Joshua A. Hirsch, MD; Guido J. Falcone, MD, MPH; Pamela W. Schaefer, MD; Michael H. Lev, MD; James D. Rabinov, MD; Natalia S. Rost, MD, MPH; Lee Schwamm, MD; R. Gilberto González, MD

Importance  Which imaging modality is optimal to select patients for endovascular stroke treatment remains unclear.

Objective  To evaluate the effectiveness of specific magnetic resonance imaging (MRI) and clinical criteria in the selection of patients with acute ischemic stroke for thrombectomy.

Design, Setting, and Participants  In ...

Original Investigation 
Henrik Zetterberg, MD, PhD; Tobias Skillbäck, MD; Niklas Mattsson, MD, PhD; John Q. Trojanowski, MD, PhD; Erik Portelius, PhD; Leslie M. Shaw, PhD; Michael W. Weiner, MD, PhD; Kaj Blennow, MD, PhD; for the Alzheimer’s Disease Neuroimaging Initiative

Importance  The extent to which large-caliber axonal degeneration contributes to Alzheimer disease (AD) progression is unknown. Cerebrospinal fluid (CSF) neurofilament light (NFL) concentration is a general marker of damage to large-caliber myelinated axons.

Objective  To test whether CSF NFL concentration is associated with cognitive decline and ...

JAMA Neurology Clinical Challenge 
Simona Lattanzi, MD; Leandro Provinciali, MD

A woman in her 30s presented with acute-onset sleepiness and decrease in consciousness, no history of neurologic disease or substance use, and laboratory findings within reference ranges. What is your diagnosis?

Tiffany Cossey, MD; Nicole R. Gonzales, MD

Intravenous tissue plasminogen activator (tPA) improves outcomes when administered within 4.5 hours of symptom onset of ischemic stroke.1 Symptomatic intracranial hemorrhage (sICH) is the most feared complication after administration of intravenous tPA. The percentage of patients with a good functional outcome after sICH (as defined by the ...

Original Investigation 
Emma Devenney, MRCP; Lauren Bartley, BSc; Chris Hoon, BSc; Claire O’Callaghan, MD; Fiona Kumfor, PhD; Michael Hornberger, PhD; John B. Kwok, PhD; Glenda M. Halliday, PhD; Matthew C. Kiernan, FRACP; Olivier Piguet, PhD; John R. Hodges, MD, FRCP
Includes: Supplemental Content

Importance  A gap in the literature exists regarding progression in behavioral variant frontotemporal dementia (BVFTD). Guidance is needed concerning markers that will enable clinicians to discriminate FTD more effectively from phenocopies and to identify factors that determine progression and thereby prognosis.

Objectives  To observe longitudinal outcomes ...

Original Investigation 
Shadi Yaghi, MD; Amelia K. Boehme, MSPH, PhD; Jamil Dibu, MD; Christopher R Leon Guerrero, MD; Syed Ali, MD; Sheryl Martin-Schild, MD, PhD; Kara A. Sands, MD; Ali Reza Noorian, MD; Christina A. Blum, MD; Shuchi Chaudhary, MD; Lee H. Schwamm, MD; David S. Liebeskind, MD; Randolph S. Marshall, MD, MS; Joshua Z. Willey, MD, MS
Includes: Supplemental Content

Importance  Treatments for symptomatic intracerebral hemorrhage (sICH) are based on expert opinion, with limited data available on efficacy.

Objective  To better understand the natural history of thrombolysis-related sICH, with a focus on the efficacy of various treatments used.

Design, Setting, and Participants  Multicenter retrospective study ...

Editorial: Thrombolysis-Related Hemorrhage; Tiffany Cossey, MD; Nicole R. Gonzales, MD
Clinical Pathologic Conference 
Nathan H. Kung, MD; Nancy L. Bartlett, MD; Nabeel R. Yaseen, MD; Gregory P. Van Stavern, MD; Robert C. Bucelli, MD, PhD
Includes: Supplemental Content

A 29-year-old woman presented with blurred vision and distal paresthesias. Her initial evaluation revealed severe bilateral optic disc edema with distal lower-extremity sensory and motor deficits and electrodiagnostic evidence of a length-dependent mixed demyelinating and axonal polyneuropathy. The results of routine diagnostic testing, including laboratory tests, magnetic resonance ...

Images in Neurology 
Meital Ben-Dov, MD; Edna Inbar, MD; Israel Steiner, MD, FRCP

This case report describes a man with confusion and somnolence who had massive infarcts with episodes of bleeding into the thalami and basal ganglia consistent with a filling defect extending throughout the patient’s straight sinus.

Nicholas D. Schiff, MD

A study by Fernández-Espejo et al1 in this issue of JAMA Neurology addresses the important question of what underlying brain mechanisms may account for the sharp dissociation of a retained but unrecognized (covert) cognitive capacity in some severely brain-injured patients with nonpurposeful or absent behavioral responses. During ...

Original Investigation  FREE
Davinia Fernández-Espejo, PhD; Stephanie Rossit, PhD; Adrian M. Owen, PhD
Includes: Supplemental Content

Importance  It is well accepted that a significant number of patients in a vegetative state are covertly aware and capable of following commands by modulating their neural responses in motor imagery tasks despite remaining nonresponsive behaviorally. To date, there have been few attempts to explain this dissociation ...

Original Investigation 
Jonathan Gooblar, MA; Catherine M. Roe, PhD; Natalie J. Selsor, MSW; Matthew J. Gabel, PhD; John C. Morris, MD
Includes: Supplemental Content

Importance  Results of Alzheimer disease (AD) research assessments typically are not disclosed to participants. Recent research has suggested interest in disclosure, but, to our knowledge, few studies have accounted for awareness of potential benefits and limitations of disclosure.

Objective  To determine the attitudes of cognitively normal ...

Images in Neurology 
Berend Feddersen, MD, PhD; Christian Vollmar, MD; Jan Rémi, MD; Thomas Stephan, PhD; Virginia L. Flanagin, PhD; Soheyl Noachtar, MD
Includes: Supplemental Content

This case report describes a patient who had hypoxia and posthypoxic intention myoclonus and subsequently developed clonic seizures while solving sudoku puzzles.

Between 1993 and 2015, the US Food and Drug Administration (FDA) approved 13 drugs for the treatment of relapsing-remitting multiple sclerosis (MS). While these disease-modifying therapies (DMTs) fall into 7 different categories and vary in route of administration, adverse effects, and efficacy, they have one commonality—they are all ...

Original Investigation 
Serena Ruggieri, MD; Maria Petracca, MD; Aaron Miller, MD; Stephen Krieger, MD; Rezwan Ghassemi, PhD; Yadira Bencosme, CCRC; Claire Riley, MD; Jonathan Howard, MD; Fred Lublin, MD; Matilde Inglese, MD, PhD

Importance  The investigation of cortical gray matter (GM), deep GM nuclei, and spinal cord damage in patients with primary progressive multiple sclerosis (PP-MS) provides insights into the neurodegenerative process responsible for clinical progression of MS.

Objective  To investigate the association of magnetic resonance imaging measures of ...

Original Investigation 
Jeffrey Cohen, MD; Anna Belova, MD; Krzysztof Selmaj, MD; Christian Wolf, MD; Maria Pia Sormani, PhD; Janine Oberyé, MSc; Evelyn van den Tweel, PhD; Roel Mulder; Norbert Koper, PhD; Gerrit Voortman, MSc; Frederik Barkhof, MD; for the Glatiramer Acetate Clinical Trial to Assess Equivalence With Copaxone (GATE) Study Group
Includes: Supplemental Content

Importance  The patents for the first approved treatments for relapsing-remitting multiple sclerosis are expiring, creating the opportunity to develop generic alternatives.

Objective  To evaluate in the Glatiramer Acetate Clinical Trial to Assess Equivalence With Copaxone (GATE) study whether generic glatiramer acetate (hereafter generic drug) is equivalent ...

Editorial: Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate; Dennis Bourdette, MD; Daniel Hartung, PharmD, MPH
Original Investigation 
Kathryn C. Fitzgerald, ScM; Kassandra L. Munger, ScD; Karl Köchert, MD; Barry G. W. Arnason, MD; Giancarlo Comi, MD; Stuart Cook, MD; Douglas S. Goodin, MD; Massimo Filippi, MD; Hans-Peter Hartung, MD, FRCP; Douglas R. Jeffery, MD, PhD; Paul O’Connor, MD; Gustavo Suarez, MD; Rupert Sandbrink, MD, PhD; Ludwig Kappos, MD; Christoph Pohl, MD†; Alberto Ascherio, MD, DrPH
Includes: Supplemental Content

Importance  Low serum 25-hydroxyvitamin D (25[OH]D) levels are associated with an increased risk of multiple sclerosis (MS) as well as with increased disease activity and rate of progression in clinically isolated syndromes and early MS.

Objective  To assess the association between 25(OH)D and disease course and ...

Louis R. Caplan, MD; Anthony J. Furlan, MD; Werner Hacke, MD, PhD

This Viewpoint discusses the future of thrombolysis and thrombectomy for patients with acute brain ischemia.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts